AMICUS THERAPEUTICS, INC.FOLDEarnings & Financial Report
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Revenue
$141.5M
Gross Profit
$128.2M
Operating Profit
$21.7M
Net Profit
$-6.7M
Gross Margin
90.6%
Operating Margin
15.3%
Net Margin
-4.8%
YoY Growth
36.7%
EPS
$-0.02
AMICUS THERAPEUTICS, INC. Q3 FY2024 Financial Summary
AMICUS THERAPEUTICS, INC. reported revenue of $141.5M (up 36.7% YoY) for Q3 FY2024, with a net profit of $-6.7M (up 68.8% YoY) (-4.8% margin). Cost of goods sold was $13.3M, operating expenses totaled $106.6M.
Key Financial Metrics
| Total Revenue | $141.5M |
|---|---|
| Net Profit | $-6.7M |
| Gross Margin | 90.6% |
| Operating Margin | 15.3% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
AMICUS THERAPEUTICS, INC. Q3 FY2024 revenue of $141.5M breaks down across 2 segments, led by Galafold at $120.4M (85.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Galafold | $120.4M | 85.1% |
| Pombiliti Opfolda | $21.1M | 14.9% |
AMICUS THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
AMICUS THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Galafold and Pombiliti Opfolda) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Galafold | $64.8M | $57.2M | $53.6M | — |
| Pombiliti Opfolda | $14.6M | $13.1M | $10.7M | — |
AMICUS THERAPEUTICS, INC. Annual Revenue by Year
AMICUS THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $634.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $634.2M |
| 2024 | $528.3M |
| 2023 | $399.4M |
| 2022 | $329.2M |
AMICUS THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
AMICUS THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $185.2M | +23.7% | $1.7M | 0.9% |
| Q3 FY2025 | $169.1M | +19.5% | $17.3M | 10.2% |
| Q2 FY2025 | $154.7M | +22.1% | $-24.4M | -15.8% |
| Q1 FY2025 | $125.2M | +13.4% | $-21.7M | -17.3% |
| Q4 FY2024 | $149.7M | +30.1% | $14.7M | 9.8% |
| Q3 FY2024 | $141.5M | +36.7% | $-6.7M | -4.8% |
| Q2 FY2024 | $126.7M | +34.0% | $-15.7M | -12.4% |
| Q1 FY2024 | $110.4M | +28.0% | $-48.4M | -43.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $110.4M | $126.7M | $141.5M | $149.7M | $125.2M | $154.7M | $169.1M | $185.2M |
| YoY Growth | 28.0% | 34.0% | 36.7% | 30.1% | 13.4% | 22.1% | 19.5% | 23.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $721.8M | $749.5M | $786.6M | $785.0M | $789.8M | $815.3M | $868.8M | $949.9M |
| Liabilities | $591.1M | $617.0M | $607.7M | $591.0M | $596.3M | $611.0M | $638.4M | $675.6M |
| Equity | $130.7M | $132.5M | $178.8M | $194.0M | $193.6M | $204.3M | $230.4M | $274.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.7M | $22.7M | $-23.0M | $-3.9M | $7.8M | $-26.5M | $35.7M | $16.3M |